Abeona Therapeutics' (ABEO) "Buy" Rating Reaffirmed at HC Wainwright

Leslie Hanson
October 12, 2017

The stock has Return on Assets (ROA) of -23.9 percent.

Short traders are feeling a little more bearish on shares of the company lately as implied by the increase in short interest. EOG Resources Inc (NYSE:EOG) has risen 17.15% since October 10, 2016 and is uptrending.

Previously on 10/10/2017, Citigroup reported about Abeona Therapeutics (NASDAQ:ABEO) upped the target price from $0.00 to $32.00 that suggested an upside of 0.83%. Therefore 100% are positive.

Insider Trading Activity for Abeona Therapeutics Inc. $20.83's average target is 14.45% above currents $18.2 stock price. As per Thursday, September 14, the company rating was initiated by RBC Capital Markets. H.C. Wainwright maintained it with "Buy" rating and $2000 target in Wednesday, July 19 report. Jefferies maintained it with "Buy" rating and $27.0 target in Friday, October 6 report. The firm earned "Buy" rating on Wednesday, April 20 by Rodman & Renshaw. The stock of Abeona Therapeutics Inc (NASDAQ:ABEO) has "Buy" rating given on Thursday, September 8 by Cantor Fitzgerald. The firm has "Buy" rating by Maxim Group given on Tuesday, August 29. Finally, Jefferies Group LLC reiterated a buy rating and issued a $22.00 price target on shares of Abeona Therapeutics in a report on Thursday, June 22nd. The rating was maintained by H.C. Wainwright with "Buy" on Monday, October 9. Looking at the stock's movement on the chart, Abeona Therapeutics Inc. recorded a 52-week high of $18.90. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.07). The scale runs from 1 to 5 with 1 recommending Strong Buy and 5 recommending a Strong Sell.

Abeona Therapeutics Inc. (ABEO) has the market capitalization of $755.91 Million. It has outperformed by 134.32% the S&P500. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced today that two patients were enrolled in the Company's ABO-102 Phase 1/2 clinical trial, at sites in Australia and the US. The company has market cap of $833.95 million. In August, its shares jumped higher when the FDA granted EB-101 a breakthrough therapy designation for the treatment of recessive dystrophic epidermolysis bullosa, a debilitating skin disease. A negative earnings surprise will usually result in a decline in share price. In the previous year there have been a total of 1 insider trades, including 1 open market buys and 0 sells. Short shares increased 1,241,967 over that period. Its down 0.66, from 2.63 in 2017Q1.

Investors as well as the sell-side will be paying close attention to how the actual numbers compare with the estimates. 74 funds opened positions while 313 raised stakes. Moller Svcs has 37,915 shares. Perhaps, that suggests something about why 34.81% of the outstanding share supply is held by institutional investors. Marble Harbor Investment Counsel Limited Liability owns 200,632 shares. Axa reported 0.44% in General Electric Company (NYSE:GE). Bank of New York Mellon Corp boosted its holdings in shares of Abeona Therapeutics by 125.8% during the first quarter. J. Goldman & Co Lp owns 305,000 shares valued at $1,952,000. Wells Fargo Mn owns 149,671 shares or 0% of their U.S. portfolio. Pictet North America Advsr Sa holds 3,707 shares or 0.06% of its portfolio. Snow Mgmt LP holds 0.03% or 22,486 shares in its portfolio.

On 7/31/2015 Mark J Ahn, Director, bought 18,182 with an average share price of $5.50 per share and the total transaction amounting to $100,001.00.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Other reports by Iphone Fresh

Discuss This Article